Neoprobe signs distribution deal with Syncor International (US)
This article was originally published in Clinica
Syncor International (US) is to distribute Neoprobe's RIGScan cancer detection radiopharmaceuticals in North America and other selected countries. Neoprobe plans to prepare marketing submissions for its first RIGScan product, CR49, in the US by the end of this year, with European dossiers ready for the first quarter of 1996. The RIGScan CR49 is a radiolabelled monoclonal antibody which targets specific antigens produced by colorectal cancer.